Next Article in Journal
Single and Repeated Exposure to Cannabidiol Differently Modulate BDNF Expression and Signaling in the Cortico-Striatal Brain Network
Previous Article in Journal
Effects of a Phosphodiesterase inhibitor on the Browning of Adipose Tissue in Mice
Previous Article in Special Issue
3D Human Organoids: The Next “Viral” Model for the Molecular Basis of Infectious Diseases
 
 
Article

Exploiting Bacteria for Improving Hypoxemia of COVID-19 Patients

1
Department of Public Health and Infectious Diseases Sapienza, University of Rome, 00185 Rome, Italy
2
Department of Life, Health & Environmental Sciences, University of L’Aquila, 67100 L’Aquila, Italy
3
Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, 67100 L’Aquila, Italy
*
Author to whom correspondence should be addressed.
Academic Editors: Amedeo Amedei and Irena Mladenova
Biomedicines 2022, 10(8), 1851; https://doi.org/10.3390/biomedicines10081851
Received: 10 June 2022 / Revised: 27 July 2022 / Accepted: 28 July 2022 / Published: 1 August 2022
(This article belongs to the Special Issue Molecular Research in Infectious Diseases)
Background: Although useful in the time-race against COVID-19, CPAP cannot provide oxygen over the physiological limits imposed by severe pulmonary impairments. In previous studies, we reported that the administration of the SLAB51 probiotics reduced risk of developing respiratory failure in severe COVID-19 patients through the activation of oxygen sparing mechanisms providing additional oxygen to organs critical for survival. Methods: This “real life” study is a retrospective analysis of SARS-CoV-2 infected patients with hypoxaemic acute respiratory failure secondary to COVID-19 pneumonia undergoing CPAP treatment. A group of patients managed with ad interim routinely used therapy (RUT) were compared to a second group treated with RUT associated with SLAB51 oral bacteriotherapy (OB). Results: At baseline, patients receiving SLAB51 showed significantly lower blood oxygenation than controls. An opposite condition was observed after 3 days of treatment, despite the significantly reduced amount of oxygen received by patients taking SLAB51. At 7 days, a lower prevalence of COVID-19 patients needing CPAP in the group taking probiotics was observed. The administration of SLAB51 is a complementary approach for ameliorating oxygenation conditions at the systemic level. Conclusion: This study proves that probiotic administration results in an additional boost in alleviating hypoxic conditions, permitting to limit on the use of CPAP and its contraindications. View Full-Text
Keywords: oxygen; CPAP; probiotics; SLAB51 oxygen; CPAP; probiotics; SLAB51
Show Figures

Figure 1

MDPI and ACS Style

Trinchieri, V.; Marazzato, M.; Ceccarelli, G.; Lombardi, F.; Piccirilli, A.; Santinelli, L.; Maddaloni, L.; Vassalini, P.; Mastroianni, C.M.; d’Ettorre, G. Exploiting Bacteria for Improving Hypoxemia of COVID-19 Patients. Biomedicines 2022, 10, 1851. https://doi.org/10.3390/biomedicines10081851

AMA Style

Trinchieri V, Marazzato M, Ceccarelli G, Lombardi F, Piccirilli A, Santinelli L, Maddaloni L, Vassalini P, Mastroianni CM, d’Ettorre G. Exploiting Bacteria for Improving Hypoxemia of COVID-19 Patients. Biomedicines. 2022; 10(8):1851. https://doi.org/10.3390/biomedicines10081851

Chicago/Turabian Style

Trinchieri, Vito, Massimiliano Marazzato, Giancarlo Ceccarelli, Francesca Lombardi, Alessandra Piccirilli, Letizia Santinelli, Luca Maddaloni, Paolo Vassalini, Claudio Maria Mastroianni, and Gabriella d’Ettorre. 2022. "Exploiting Bacteria for Improving Hypoxemia of COVID-19 Patients" Biomedicines 10, no. 8: 1851. https://doi.org/10.3390/biomedicines10081851

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop